Physician profile
Joseph A James
NPI 1699761221
$4,055.02
in general payments reported to CMS, 2019-2025
37 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $575 · 2021: $437 · 2022: $950 · 2023: $446 · 2024: $413 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $517.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $487.81 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $339.06 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Abbott Laboratories | $301.65 | 2020-2024 | Freestyle Libre 3, Proclaim |
| Abbvie INC. | $298.69 | 2021-2023 | |
| Pfizer INC. | $248.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $243.72 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.94 | 2019-2025 | Xifaxan |
| Amgen INC. | $158.92 | 2019-2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $149.39 | 2022 | |
| Astellas Pharma US INC | $124.06 | 2019-2023 | Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.12 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $110.61 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.79 | 2022-2024 | |
| Dynavax Technologies Corporation | $80.45 | 2019-2023 | Heplisav-B |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $76.53 | 2019-2021 | |
| Exact Sciences Corporation | $68.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $67.21 | 2019-2020 | |
| Boston Scientific Corporation | $50.95 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $40.68 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $34.02 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.31 | 2021 | |
| Scilex Pharmaceuticals INC. | $31.12 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $27.70 | 2021 | |
| Esperion Therapeutics, INC. | $25.71 | 2021-2022 | |
| Eisai INC. | $21.62 | 2019 | |
| Dexcom, INC. | $20.43 | 2024 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $17.74 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Watermark Medical, INC. | $17.64 | 2024 | |
| Biogen, INC. | $16.44 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.11 | 2025 | Caplyta |
| Adlon Therapeutics L.P. | $12.97 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.38 | 2019 | |
| Sanofi Pasteur INC. | $11.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.44 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.